Core Points - President Trump claims his settlement with Paramount Global is valued at over $32 million, which is more than double the company's stated figure of $16 million [1][3][4] - The settlement includes a side deal for public service announcements (PSAs) valued between $15 million and $20 million, promoting causes supported by Trump [2][15] - Paramount has denied any connection between the settlement and the pending $8 billion merger with Skydance Media, asserting that the settlement does not include PSAs [8][4] Company Details - The settlement covers payments for Trump's future presidential library and legal fees, with "60 Minutes" agreeing to release interview transcripts after airing [7][10] - Paramount's initial offer was $15 million, which was later negotiated down from Trump's original demand of $100 million to around $50 million [11] - High-level negotiations included pressure from Paramount's controlling shareholder, Shari Redstone, to settle the dispute to avoid potential legal costs [13][14]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged misrepresentations regarding the safety risks of its product ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Sarepta and certain senior officers [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by August 25, 2025, with the option to remain as absent class members if they choose not to take action [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Points - Paramount settled with President Trump for $16 million over alleged edits in "60 Minutes" that Trump claimed favored Kamala Harris, leading to media criticism [2] - The settlement funds are intended to cover Trump's legal fees and contribute to his Presidential Library, similar to previous settlements with other media companies [3] - The IRS may view settlement payments for legal fees as taxable income, depending on whether the fees were previously deducted [5][6] Tax Implications - Settling lawsuits with funds directed to charity may not always provide a complete tax solution, as the IRS may treat it as a payment to the plaintiff first [4][7] - Legal settlements are generally taxable based on the origin of the claim, with specific rules and exceptions that can complicate tax obligations [8] - Mental anguish claims, such as those made by Trump regarding the "60 Minutes" edits, do not qualify for tax exclusions under current IRS rules [10] Legal Fees and Taxation - Legal fees can complicate tax situations, as plaintiffs are treated as receiving the full settlement amount for tax purposes, regardless of how much is paid to their attorney [12][13] - Punitive damages and interest from settlements are always taxable, which can affect the overall tax liability of the plaintiff [14]

LOS ANGELES, July 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against 3D Systems Corporation ("3D Systems" or "the Company") (NYSE: DDD) for violations of securities laws.Shareholders who purchased the Company's securities between August 13, 2024 and May 13, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 12, 2025.CASE DETAILS: The Complaint claims that the Company made false and misleading statements to the market. 3D Systems ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price after the FDA placed a clinical hold on the study following a Serious Adverse Event [2][3]. Group 1: Allegations and Events - The lawsuit claims that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) and participant deaths [2]. - The company amended the clinical trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a patient's death, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [2]. Group 2: Shareholder Actions - Shareholders who purchased RCKT shares during the class period from February 27, 2025, to May 26, 2025, are encouraged to register for the class action and may seek lead plaintiff status by the deadline of August 11, 2025 [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [3]. Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Vestis Corporation regarding a class action lawsuit due to allegations of misleading statements and failure to meet growth expectations, resulting in a significant stock price decline [1][2]. Group 1: Allegations and Financial Impact - The class period for the allegations against Vestis Corporation is from May 2, 2024, to May 6, 2025 [2]. - The complaint states that Vestis provided overly positive statements while concealing material adverse facts about its business growth capabilities, particularly regarding customer experience and retention [2]. - Following the announcement of disappointing financial results for Q2 fiscal 2025 and the withdrawal of revenue guidance, Vestis' stock price plummeted from $8.71 to $5.44, a decline of approximately 37.54% in one day [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action lawsuit by August 8, 2025, to potentially become lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4].

NEW YORK, July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Digimarc Corporation (NASDAQ: DMRC).Shareholders who purchased shares of DMRC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/digimarc-corporation-loss-submission-form-2/?id=155400&from=4CLASS PERIOD: May 3, 202 ...

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims & Hers Health, Inc. is from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements made by the defendants about the company's business and operations lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline of August 25, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Petco Health and Wellness Company, Inc. is facing allegations regarding the sustainability of its business model and the accuracy of its public statements, particularly related to its pandemic-driven growth and product strategy [2]. Group 1: Allegations and Class Action Details - The class period for the allegations against Petco spans from January 14, 2021, to June 5, 2025 [2]. - Allegations include that Petco's pandemic-related growth was unsustainable and that its premium pet food business model was overstated [2]. - Defendants are accused of downplaying the severity of issues affecting the company and overstating its ability to achieve sustainable, profitable growth [2]. Group 2: Shareholder Actions - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by the deadline of August 29, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case does not incur any costs or obligations for the shareholders [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Rocket Companies, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical financial information during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from March 29, 2021, to April 1, 2021, Rocket's gain on sale margins were contracting at the highest rate in two years due to increased competition among mortgage lenders and a shift towards lower margin segments [2]. - It is claimed that Rocket was engaged in a price war with competitors, further compressing margins in its Partner Network operating segment [2]. - The adverse trends were reportedly accelerating, with gain on sale margins expected to plummet by at least 140 basis points in the first half of 2021 [2]. - The favorable market conditions that had previously allowed Rocket to achieve high gain on sale margins had disappeared, returning to levels not seen since Q1 2019 [2]. - Company-wide gain-on-sale margins had fallen materially below recent historical averages, contradicting earlier positive statements made by the defendants [2]. Next Steps for Shareholders - Shareholders who purchased shares of RKT during the specified timeframe are encouraged to register for the class action by July 8, 2025, to potentially be appointed as lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [3]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceitful practices [4].